Most patients with chronic hepatitis C who had been ineligible for or
nonresponsive to interferon-based treatment benefited from dual therapy
with daclatasvir and asunaprevir in a recent study.
In an open-label, phase 2a study, researchers administered 24 weeks
of dual oral therapy with 60 mg NS5A replication complex inhibitor
daclatasvir (DCV) once daily and 200 mg NS3 protease inhibitor
asunaprevir (ASV) twice a day to 43 Japanese patients aged 20 to 75
years with chronic HCV
genotype 1b. The cohort included 21 null responders and 22 who had been
ineligible or intolerant to previous therapy with pegylated
interferon-alfa and ribavirin (PegIFN-a/RBV).